Abstract Body

Background

Data on HPV-specific T-cell responses to the nonavalent Gardasil 9® vaccine in people with HIV(PWH) are limited. Given the critical role of cellular mediated-immunity(CMI) in vaccine efficacy, we evaluated post-vaccination T-cell responses in virally suppressed PWH on ART, stratified by CD4 T-cell count at time of first vaccine dose.

Methods

We prospectively enrolled PWH on ART. Inclusion criteria were age ≥ 18 years, undergoing ART for at least 6 months, and being naïve to HPV vaccination. Gardasil9® was administered at baseline(T0), after 2 and 6 months(T1); follow-up continued to 1 year(T2) up to 2 years(T3). Blood samples were collected for viro-immunological follow-up and to evaluate CMI by flow cytometry of CD4 and CD8 T cells producing IFN-γ, IL-2, and TNFα(responding) and all three cytokines(polyfunctional) after stimulation with a pool of HPV16 and 18. Adjusted linear mixed models with random intercepts and slopes for individuals and robust standard errors were used to estimate mean levels of CD4 and CD8 responding and polyfunctional cells comparing groups stratified by baseline CD4(>500 vs ≤500 cells/μL). Models were adjusted for age, sex, CD4 nadir, HIV viral load suppression and CD4 at baseline. Mean changes from T1 to T0, T2 to T0 and T3 to T0 between groups are reported with 95% confidence intervals. 

Results

A total of 38 patients were enrolled; current T3 data were available for 17 patients out of 38(44,7%). The analysis of the estimated change from T0 revealed significant associations between higher CD4 counts and improved immune responses at earlier time-points. Specifically, at T1, participants with >500 CD4 cells/µl showed significantly greater increases in CD4-responding (+1.19[95% CI: +0.28,+2.10],p=0.010), CD4polyfunctional (+0.057[95% CI: +0.014, +0.100],p=0.009), and CD8-responding(+1.46 [95% CI:+0.65,+2.27],p=0.010) responses compared to those with ≤500 CD4 cells/µl. At T2, a significant difference persisted for CD8-responding cells(+2.32[95% CI:+0.51,+4.14],p=0.012). By T3, most differences were no longer significant, except for CD8-polyfunctional cells, where a significant decrease was observed in the>500 CD4 group compared to the ≤500 group(Δ =–0.0044[95% CI:–0.0208,–0.0049],p=0.001). 

Conclusions

Higher baseline CD4 counts are associated with stronger early immune responses to HPV vaccination in PWH. Tailored vaccination schedules and follow-up may be warranted in PWH, particularly among them with lower CD4 levels to ensure optimal and sustained protection.